175357-98-9

Basic information

• Product Name: 4-CHLORO-6-FLUOROPYRIDO[3,4-D]PYRIMIDINE
• Synonyms: 4-CHLORO-6-FLUOROPYRIDO[3,4-D]PYRIMIDINE;Pyrido[3,4-d]pyriMidine,4-chloro-6-fluoro-
• CAS NO: 175357-98-9
• Molecular Formula: C₇H₃ClFN₃
• Molecular Weight: 183.5702232
• Product Categories: CHIRAL CHEMICALS
• Mol File: 175357-98-9.mol
• Article Data: 15

Chemical Properties

• Boiling Point: 331.65 °C at 760 mmHg
• Flash Point: 154.377 °C
• Appearance: /
• Density: 1.537±0.06 g/cm3 (20 ºC 760 Torr)
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.645
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 0.82±0.30(Predicted)
• CAS DataBase Reference: 4-CHLORO-6-FLUOROPYRIDO[3,4-D]PYRIMIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-CHLORO-6-FLUOROPYRIDO[3,4-D]PYRIMIDINE(175357-98-9)
• EPA Substance Registry System: 4-CHLORO-6-FLUOROPYRIDO[3,4-D]PYRIMIDINE(175357-98-9)

Safety Data

• Hazardous Substances Data: 175357-98-9(Hazardous Substances Data)

Usage

General Description

4-CHLORO-6-FLUOROPYRIDO[3,4-D]PYRIMIDINE is a chemical compound with the molecular formula C5H2ClFN4. It is a pyrido[3,4-d]pyrimidine derivative, which consists of a pyridine ring fused to a pyrimidine ring. The compound is a halogenated derivative, containing both chlorine and fluorine atoms. This chemical may have applications in pharmaceutical research and development, as well as in other industrial processes. Its specific properties and potential uses would depend on its purity, stability, and other characteristics.

InChI:InChI=1/C7H3ClFN3/c8-7-4-1-6(9)10-2-5(4)11-3-12-7/h1-3H

Upstream product

• 68-12-2 N,N-dimethyl-formamide 
• 171178-44-2 6-fluoro-4-oxo-3H-pyrido[3,4-d]pyrimidine 
• 171178-42-0 5-[N-(tert-Butoxycarbonyl)-amino]-2-fluoropyridine-4-carboxylic acid 
• 1827-27-6 2-fluoro-5-aminopyridine 
• 171178-41-9 (6-fluoro-pyridin-3-yl)-carbamic acid, tert-butyl ester 
• 171178-43-1 5-Amino-2-fluoropyridine-4-carboxylic acid 

Downstream Products

• 2135696-72-7 (E)-N-(4-((3-bromo-4-chlorophenyl)amino)pyrido[3,4-d]pyrimidin-6-yl)-4-(dimethylamino)but-2-enamide 
• 1222832-70-3 N⁴-(1-benzyl-1H-indazol-5-yl)pyrido[3,4-d]pyrimidine-4,6-diamine 

Relevant articles and documents

USE OF QUINAZOLINE-BASED TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCERS WITH NRG1 FUSIONS

Provided herein are methods of selecting cancer patients for treatment with quinazoline-based tyrosine kinase inhibitors, either alone or in combination with anti- HER2/HER3 antibodies, as well as methods of treating cancer patients so selected. Cancer patients are selected for treatment if their cancer has an NRG1 fusion. Selected patients are then treated with quinazoline-based tyrosine kinase inhibitors alone or in combination with anti -HER2/HER3 antibodies.

CYCLIC IMINOPYRIMIDINE DERIVATIVES AS KINASE INHIBITORS

Provided are cyclic iminopyridimdine compounds and their bicyclic derivatives, pharmaceutical compositions comprising such compounds, and methods of using such compounds or compositions, such as methods of treating a proliferation disorder, such as a cancer or a tumor, or in some embodiments disease or disorders related to the dysregulation of kinase such as, but not limited to B-Raf V600E kinase.

PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY

The invention provides novel prodrug compounds comprising a kinase inhibitor and a reductively-activated fragmenting aromatic nitroheterocycle or aromatic nitrocarbocycle trigger, where the compound carries a positive charge. In preferred embodiments, the compounds are of Formula I: where: X is any negatively charged counterion; R1 is a group of the formula —(CH2)nTr, where Tr is an aromatic nitroheterocycle or aromatic nitrocarbocycle and —(CH2)nTr acts as a reductively-activated fragmenting trigger; and n is an integer from 0 to 6; R2, R3 and R4 may each independently be selected from aliphatic or aromatic groups of a tertiary amine kinase inhibitor (R2)(R3)(R4)N, or two of R2, R3, and R4 may form an aliphatic or aromatic heterocyclic amine ring of a kinase inhibitor, or one of R2, R3 and R4 may be absent and two of R2, R3 and R4 form an aromatic heterocyclic amine ring of a kinase inhibitor. The compounds of the invention are useful in treating proliferative diseases such as cancer.